Vitamin D deficiency affects about 42% of US adults and far more in dark-skinned populations, and this entry argues the 30 ng/mL threshold marks adequacy against rickets rather than optimal health. The evidence splits by baseline status: meta-analyses find lower cancer and all-cause mortality mainly in deficient or older subgroups, while VITAL and D-Health found no benefit in largely replete populations. Mendelian randomization supports a causal role for low vitamin D in MS, type 1 diabetes and mortality.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does vitamin D supplementation reduce mortality?
In deficient populations, meta-analyses suggest yes: a 2025 meta-analysis of 14 RCTs with over 100,000 participants found daily D3 reduced cancer mortality 12%, and up to 16% in people over 70 or below 20 ng/mL at baseline. VITAL and D-Health were null but enrolled largely vitamin-D-replete participants.3
Is vitamin D deficiency common?
Very. About 41.6% of US adults fall below 20 ng/mL, with rates of 82% in Black Americans and 69% in Hispanic Americans, and an estimated one billion people deficient worldwide. Dark skin, age, obesity and sun avoidance all drive it.
What is the optimal vitamin D level?
Debated. The 30 ng/mL threshold prevents rickets; the entry cites observational data putting lowest mortality at 50-70 ng/mL while acknowledging trials in already-sufficient people show no benefit. Optimal appears to depend on baseline status.
Does vitamin D need cofactors?
The entry argues yes: vitamin D raises calcium absorption, which without K2 may deposit in arteries rather than bone, and magnesium is required for vitamin D metabolism. These are mechanistic arguments rather than proven requirements.
What would change this rating?
Large randomized trials enrolling only deficient participants. The entry's whole reading rests on the claim that VITAL and D-Health were null because their participants were already replete, a hypothesis that has not been directly tested at scale.3
Core thesis: Vitamin D deficiency is near-universal in modern populations, yet optimal levels (likely 40-60+ ng/mL, not the inadequate 30 ng/mL threshold) may be critical for immune function, hormonal health, and disease prevention. The mainstream 600-800 IU recommendation is grossly insufficient for most people.
02The Deficiency Crisis
Why Everyone Is Deficient
- Sun avoidance: Modern indoor lifestyles, sunscreen use, latitude north of 37° eliminates most vitamin D synthesis
- Dark skin: Melanin blocks UVB conversion; dark-skinned individuals need 5-10x more sun exposure
- Aging: Skin's 7-dehydrocholesterol decreases with age; seniors synthesize 75% less vitamin D from same sun exposure
- Obesity: Vitamin D is fat-soluble and sequestered in adipose tissue, reducing bioavailability
- Gut issues: Malabsorption syndromes, celiac disease, Crohn's impair absorption
Prevalence
- Estimated 1 billion people worldwide have vitamin D deficiency
- 41.6% of US adults are deficient (<20 ng/mL)
- 82.1% of Black Americans and 69.2% of Hispanics are deficient
03Optimal Blood Levels
| Serum 25(OH)D | Classification | Implications |
|---|---|---|
| <10 ng/mL | Severe deficiency | Rickets (children), osteomalacia (adults) |
| 10-20 ng/mL | Deficiency | Increased fracture risk, immune dysfunction |
| 20-30 ng/mL | Insufficiency | Suboptimal for many physiological functions |
| 30-50 ng/mL | Conventional normal | Inadequate for optimal health per many researchers |
| 50-80 ng/mL | Optimal range | Associated with lowest all-cause mortality |
| 80-100 ng/mL | High-normal | May be optimal for some conditions |
| >100 ng/mL | Potential excess | Monitor for toxicity (rare) |
Swipe table →
The 30 ng/mL Myth
The 30 ng/mL threshold represents the level needed to prevent rickets/osteomalacia, not optimal health. Many functional medicine practitioners argue: - Observational studies show U-shaped curve with lowest mortality at 50-70 ng/mL - Autoimmune diseases show dose-response relationship up to higher levels - GrassrootsHealth data suggests 60-80 ng/mL for optimal immune function
04Doses in studies
Loading Phase (8-12 weeks)
For severe deficiency (<20 ng/mL):
Maintenance Phase
After reaching target levels:
| Target Level | Daily Maintenance |
|---|---|
| 40 ng/mL | — |
| 50 ng/mL | — |
| 60+ ng/mL | — |
Swipe table →
Doses in studies
- Daily > weekly > monthly: Daily dosing produces more stable blood levels
- Studies administered with fat: Vitamin D is fat-soluble; absorption increases 50%+ with fatty meal
- Higher doses are safe: Up to 20,000-40,000 IU/day shown safe for months in studies; toxicity only at 100,000+ IU/day sustained
05Form Comparisons
D2 (Ergocalciferol) vs D3 (Cholecalciferol)
| Aspect | D2 | D3 |
|---|---|---|
| Source | Plant/ fungus (ergosterol) | Animal (lanolesterol) |
| Potency | ~50% of D3 | 100% potency |
| Half-life | Shorter (~24 hours) | Longer (~48 hours) |
| Evidence | Weaker clinical data | Stronger RCT data |
| Recommendation | Avoid | Preferred |
Swipe table →
Delivery Formats
| Form | Absorption | Notes |
|---|---|---|
| Oil-based capsules | Best | Olive oil, MCT oil bases |
| Liquid drops | Very good | Precise dosing, sublingual possible |
| Softgels | Good | Common, affordable |
| Tablets | Variable | May have absorption issues |
| Sprays | Emerging | Sublingual absorption, less data |
Swipe table →
06Critical Co-Factors
Vitamin K2 (Essential)
- Vitamin D increases calcium absorption
- Without K2, calcium deposits in arteries instead of bones
- Recommendation: 100-200 mcg K2 (MK-7 form) per 5000 IU vitamin D
- Synergistic effect on bone density and cardiovascular health
Magnesium (Essential)
- Magnesium is required for vitamin D metabolism (conversion in liver/kidneys)
- Deficiency limits vitamin D effectiveness
- Supplementing vitamin D without magnesium can deplete magnesium stores
- Recommendation: 300-500 mg elemental magnesium (glycinate, citrate, or malate)
Vitamin A
- Works synergistically with vitamin D
07Genetic Considerations
| Gene | Polymorphism | Impact |
|---|---|---|
| CYP2R1 | Various SNPs | Impaired 25-hydroxylation (reduces vitamin D activation) |
| GC (vitamin D binding protein) | Variants affect free vitamin D levels | May need higher total vitamin D |
| CYP27B1 | 1-alpha hydroxylase variants | Impaired conversion to active form |
| VDR | Receptor polymorphisms | Variable response to supplementation |
Swipe table →
08Uses
- Baseline test: 25-hydroxyvitamin D (25(OH)D), not 1,25(OH)2D
- Re-test: 8-12 weeks after starting/changing dose
- Maintenance: Annual testing once stable
- Optimal timing: No fasting required; can test any time of day
- Lab ranges: Request actual number, not "normal/not normal"
09Clinical Evidence
| Condition | Evidence | Findings |
|---|---|---|
| Bone health | Strong | Reduced fractures at >30 ng/mL; meta-analysis of Ca+D supplementation confirms BMD benefit in postmenopausal osteoporosis (BMC Musculoskelet Disord 2025;26:928) |
| Autoimmune | Moderate-Strong | — |
| Respiratory infections | Moderate | Reduced URI incidence; COVID-19 benefit confirmed in 2025 umbrella review (Petakh et al., Front Nutr 2025;12:1559471) |
| Long COVID | Emerging | RCT (Atieh 2025, MDPI Nutrients 17:304) showed K2+D3 reduced fungal translocation & inflammation markers in long COVID |
| Cardiovascular | Mixed | Lower CVD risk in observational studies; VITAL/VITAL-ancillary neutral for major CVD events |
| Cancer incidence | Mixed | No consistent reduction in incident cancer across VITAL, D-Health, ViDA |
| Cancer mortality | Moderate-Strong | 2025 DKFZ meta-analysis (14 RCTs, >100k participants): daily D3 400-2000 IU reduced all-cause cancer mortality 12% (RR 0.88, 95% CI 0.79-0.98); up to 16% reduction in age >70 and baseline <20 ng/mL |
| Sepsis/critical illness | Emerging | Multiple 2024 RCTs of calcitriol in sepsis (Sistanizad 2024, Thampi 2024); 2026 meta-analysis (Front Nutr) shows mortality benefit in deficient ICU patients |
| Mendelian randomization | Causal | Genetically-predicted 25(OH)D inversely associated with MS, T1D, all-cause mortality — supports causation beyond confounding |
| Mortality (observational) | Strong | U-shaped curve; lowest mortality at 50-70 ng/mL (Pilz 2019, reanalysis 2025) |
| Depression | Moderate | Correlation with mood; some RCT improvement |
Swipe table →
Critical Reading of Negative Trials
VITAL (25,871 participants, 2,000 IU/d, 5.3y) and D-Health (21,315, 60,000 IU/month) showed no all-cause mortality benefit in largely vitamin-D-replete populations (baseline mean ~30 ng/mL). This does NOT contradict benefit in deficient populations — it shows population-level sufficiency matters more than universal supplementation. Trials enrolling only deficient patients consistently show benefit.
10Contraindications & Cautions
| Condition | Guidance |
|---|---|
| Hypercalcemia | Do NOT supplement |
| Kidney disease | Monitor closely; may need active form (calcitriol) |
| Sarcoidosis | Monitor; may over-convert to active form |
| Granulomatous diseases | Monitor calcium |
| Certain medications | Thiazides, corticosteroids, anticonvulsants — consult provider |
Swipe table →
11Special Populations
Pregnancy
- Deficiency associated with preeclampsia, gestational diabetes, low birth weight
- Target: maintain >40 ng/mL throughout pregnancy
Elderly (>70)
- 2025 DKFZ meta-analysis: 16% cancer mortality reduction in this subgroup
- Higher baseline deficiency → larger absolute benefit
- Pair with weight-bearing exercise and K2 for fracture prevention
Dark-skinned populations
- 82% of Black Americans deficient (<20 ng/mL)
- Same physiological endpoints require 5-10x more sun exposure OR 2-3x oral dose
- Mendelian randomization studies confirm low 25(OH)D causal for adverse outcomes in this group
Critically ill / ICU
- 60-80% of ICU patients deficient
- High-dose enteral or IV cholecalciferol improves outcomes in deficient subgroup (2026 meta-analysis)
- Calcitriol (active form) trials: Sistanizad 2024, Thampi 2024 show reduced infectious biomarkers
What studies and practitioners report
Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.
- Trial 2,000 IU/day · Vitamin D3 (VITAL) US adults 50+ (men) / 55+ (women), n=25,871 PMID 30415629
- Trial 60,000 IU/month · Vitamin D3 (D-Health) Australians 60+, n=21,315 PMID 35026158
Further reading: detailed protocols
- NIH Office of Dietary Supplements: vitamin D fact sheet ods.od.nih.gov
12Connections
13Sources
- Holick MF et al. (2011). "Evaluation, Treatment, and Prevention of Vitamin D Deficiency." J Clin Endocrinol Metab . PMID 21646368PubMed 21646368
- McDonnell SL et al. (2017). "Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/mL Associated with 60% Lower Preterm Birth Risk." PLoS ONE . PMID 28686696PubMed 28686696
- Hahn J et al. (2022). "Vitamin D and Marine n-3 Fatty Acid Supplementation and Incident Autoimmune Disease: VITAL Randomized Controlled Trial." BMJ . PMID 35082189PubMed 35082189
- Dalamaga M et al. (2026). "Vitamin D and Health Outcomes: State-of-the-Art Review of Triangulated Evidence and Ongoing Controversies." Curr Nutr Rep . doi 10.1007/s13668-026-00748-2DOI 10.1007/s13668-026-00748-2
- Petakh P et al. (2025). "Effect of vitamin D supplementation on COVID-19 outcomes: an umbrella review of systematic reviews." Front Nutr 12:1559471. doi 10.3389/fnut.2025.1559471DOI 10.3389/fnut.2025.1559471
- Atieh O et al. (2025). "Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial." Nutrients 17(2):304. doi 10.3390/nu17020304DOI 10.3390/nu17020304
14Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.